
Like most other companies, the digital health firm Radiobiotics from Copenhagen has been struck by the effects of the Covid-19 virus.
The company was established just under two years ago. With the use of artificial intelligence, it aims to help radiologists pinpoint signs of disease. However, the company has been challenged by Covid-19 limitations. The US, especially, which was announced as the firm's next big growth market in spring, has proven troublesome.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app